Literature DB >> 15841200

Interferon-alpha Treatment of Hepatitis C Patients With Psychiatric Illness: Evidence-Based Risk-Benefit Assessment.

Muhamad Aly Rifai1.   

Abstract

Entities:  

Year:  2005        PMID： 15841200      PMCID： PMC1079701          DOI： 10.4088/pcc.v07n0207b

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  7 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Psychiatric comorbidity among hepatitis C-positive patients.

Authors:  S P Yovtcheva; M A Rifai; J K Moles; B J Van der Linden
Journal:  Psychosomatics       Date:  2001 Sep-Oct       Impact factor: 2.386

3.  A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

Authors:  Eric Dieperink; Samuel B Ho; Paul Thuras; Mark L Willenbring
Journal:  Psychosomatics       Date:  2003 Mar-Apr       Impact factor: 2.386

4.  The five-site health and risk study of blood-borne infections among persons with severe mental illness.

Authors:  Stanley D Rosenberg; Jeffrey W Swanson; George L Wolford; Fred C Osher; Marvin S Swartz; Susan M Essock; Marian I Butterfield; Bryan J Marsh
Journal:  Psychiatr Serv       Date:  2003-06       Impact factor: 3.084

5.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

6.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.

Authors:  Martin Schaefer; Folkhard Schmidt; Christian Folwaczny; Reinhard Lorenz; Gaby Martin; Norbert Schindlbeck; Walter Heldwein; Michael Soyka; Heinz Grunze; August Koenig; Klaus Loeschke
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

7.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391
  7 in total
  2 in total

1.  Psychiatric care of the patient with hepatitis C: a review of the literature.

Authors:  Muhamad Aly Rifai; Ondria C Gleason; Douha Sabouni
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.

Authors:  Renata Fialho; Alison Burridge; Marco Pereira; Majella Keller; Alexandra File; Jeremy Tibble; Richard Whale
Journal:  Psychopharmacology (Berl)       Date:  2015-05-15       Impact factor: 4.530
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.